Maurie Markman, MD

A Call to Action: Determining Optimal Dose, Schedule, and Appropriate Modifications for Antineoplastic Pharmaceutical Agents

November 4th 2024

The oncology community must reconsider its approach to defining optimal dosing and scheduling of antineoplastic agents.

The Escalating Need for Robust Decision Support in Oncology: Ovarian Cancer as an Example

October 24th 2024

The speed at which new drugs, combinations, and novel approaches are being introduced into routine practice presents a challenge for treating oncologists

Molecularly Targeted Therapeutics Are Precisely Aimed

October 10th 2024

Maurie Markman, MD, details how the precision-medicine paradigm is a highly rational platform for antineoplastic drug development.

The Scientific Validity of Peer-Reviewed Publications: A Concerning Situation With Implications for Oncology

October 3rd 2024

Maurie Markman, MD, discusses concerns regarding the scientific validity of peer-reviewed publications in oncology and their ramifications for the field.

Precision Cancer Medicine: The Past, Present, and Future

August 8th 2024

Dr Markman on the Association Between Obesity and Incidence of Endometrial Cancer

July 16th 2024

Maurie Markman, MD, discusses an analysis of the association between obesity and the development of endometrial cancer.

Hope: A Critical Concept in Oncology, but Open to Interpretation

July 9th 2024

Maurie Markman, MD, details the concept of hope during cancer diagnoses, touching on the announcement from Catherine, Princess of Wales.

Oncologic Supportive Care Is Absolutely Critical—But How Do We Define It?

June 7th 2024

Defining the goals of a clinical team within a cancer program or oncology practice group, where the focus will be on maximizing QOL, may be difficult.

Improved Survival in Randomized Trials: A Meaningful Outcome but Increasingly Difficult to Demonstrate

May 9th 2024

Maurie Markman, MD, expands on the debate regarding the appropriate primary outcome end point for improved clinical benefit in a trial.

The Critical Nature of Decision-Making in the Development of Phase 3 Clinical Trials

April 12th 2024

Randomized trials are widely recognized to play a pivotal role in the decision-making associated with the establishment of clinical guidelines.

Is It Time to Address the Fiscal Reality of the Cancer Care Model and Consider Alternatives?

March 25th 2024

Two items in the medical world should send chills down the spines of those considering the possible financial future of oncology care in the United States.

Phase 3 Randomized Trials: Expanding Clinically Meaningful Analysis Beyond the Stated Goals

February 9th 2024

The foundation of physician recommendations and medical/regulatory policy will be guided by the outcomes of published clinical research.

Actionable Molecular Findings: Increasingly Clinically Relevant but Also Increasingly Complex

January 31st 2024

Maurie Markman, MD, discusses the need for a decision support strategy to assist oncologists in treatment selection for patients with actionable mutations.

Outdated Terminology in Oncology: Is It Finally Time to Reassess?

January 23rd 2024

The absence of clearly articulated definitions and transparency related to how clinical trial outcomes are interpreted and utilized raise concerns.

Public Trust in Science and the Future of Cancer Care Is Crucial

January 12th 2024

Maurie Markman, MD, details how public trust is critical in the future of cancer care, diving into what leads to mistrust and misinformation today.

When Will We Acknowledge Information Overload in Oncology?

January 2nd 2024

The goal in highlighting this development is to attempt to raise awareness of the critical issue of information overload and the need for multiple involved parties to actively and aggressively search for appropriate, effective, and fiscally rational solutions.

Markman Reflects on Key Advances Made in 2023 in the Realm of Gynecologic Cancers and Beyond

December 27th 2023

Maurie Markman, MD, highlights inroads made with immunotherapy, antibody-dependent cytotoxic agents, and molecular testing across oncology.

Patient and Family Interpretations of the Language of Cancer Care

December 1st 2023

This commentary examines the use of words and expressions in the oncology domain and the implications of different interpretations by patients and their families from professionals employing this language, including academic authors and members of their clinical teams.

Dr Markman on Pragmatic Clinical Trial Designs in Ovarian Cancer

November 9th 2023

Maurie Markman, MD, discusses the importance of designing clinical trials for patients with ovarian cancer that are based on real-world data and consider the increasing complexity of treatment sequencing in this disease.

Reality Takes a Back Seat to Rhetoric Used in Objective Assessments of Cancer Treatment

November 6th 2023

It is time for society to address the critical nature of our current unsustainable oncology pharmaceutical marketplace, and it is also essential that whatever solutions are proposed and implemented do not incorporate inappropriate labeling of outcomes that negate meaningful measures of clinical benefit.